

## **Descriptions of Additional Supplementary Files**

### **Supplementary Data 1**

**Description:** List of HLA-A\*02:01 ligands generated by immunoprecipitation of pHLA complexes with antibody BB7.2 using established workflows (Fig. 1a), sequencing by high-resolution mass spectrometry in DDA mode and processing in PEAKS® (Fig. 1b). Refer to enclosed excel file. Monash University Room 214, 2/F, 15 Innovation Walk, Clayton, VIC 3800, Australia +61 3 9902 9265 anthony.purcell@monash.edu <https://research.monash.edu/en/persons/anthony-purcell> CRICOS Provider No. 00008C ABN 12 377 614 012

### **Supplementary Data 2**

**Description:** List of HLA-B\*07:02 ligands generated by immunoprecipitation of pHLA complexes with antibody W6/32 using established workflows (Fig. 1a), sequencing by high-resolution mass spectrometry in DDA mode and processing in PEAKS® (Fig. 1b). Refer to enclosed excel file.

### **Supplementary Data 3**

**Description:** HLA-A\*02:01 ligands, their T<sub>m</sub> values and transformed T<sub>m</sub> values. Refer to enclosed excel file.

### **Supplementary Data 4**

**Description:** HLA-B\*07:02 ligands, their T<sub>m</sub> values and transformed T<sub>m</sub> values. Refer to enclosed excel file.

### **Supplementary Data 5**

**Description:** HLA- C\*04:01 ligands and their T<sub>m</sub> values. Refer to enclosed excel file.

### **Supplementary Data 6**

**Description:** Includes the list of neoepitopes (26 peptides) curated from the literature by Blaha et al., the list of cancer peptides (20 peptides) confirmed to be negative in multiple subjects tested in multimer/tetramer or ELISPOT assays, retrieved from the IEDB, and the list of all confident negatives (199 peptides) from the IEDB, including all cancer, autoimmune and viral peptides.